Maze Therapeutics (NASDAQ:MAZE) Sets New 1-Year High After Analyst Upgrade

Maze Therapeutics, Inc. (NASDAQ:MAZE)’s share price hit a new 52-week high during trading on Tuesday after Wedbush raised their price target on the stock from $43.00 to $58.00. Wedbush currently has an outperform rating on the stock. Maze Therapeutics traded as high as $53.65 and last traded at $51.26, with a volume of 899720 shares changing hands. The stock had previously closed at $50.21.

Other analysts also recently issued reports about the stock. Guggenheim upped their target price on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a research report on Wednesday, March 4th. Mizuho raised shares of Maze Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 11th. HC Wainwright reissued a “buy” rating on shares of Maze Therapeutics in a research note on Wednesday, January 28th. BTIG Research reaffirmed a “buy” rating and set a $46.00 target price on shares of Maze Therapeutics in a research note on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a report on Thursday, January 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $57.38.

Insiders Place Their Bets

In related news, insider Atul Dandekar sold 72,400 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $2,936,544.00. Following the completion of the sale, the insider owned 10,503 shares of the company’s stock, valued at $426,001.68. This trade represents a 87.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Harold Bernstein sold 45,000 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $40.56, for a total transaction of $1,825,200.00. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 230,000 shares of company stock valued at $9,768,292.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Frazier Life Sciences Management L.P. lifted its holdings in shares of Maze Therapeutics by 10.6% during the second quarter. Frazier Life Sciences Management L.P. now owns 4,567,275 shares of the company’s stock valued at $56,040,000 after purchasing an additional 438,274 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Maze Therapeutics by 318.0% in the 4th quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares in the last quarter. Vanguard Group Inc. increased its holdings in Maze Therapeutics by 27.1% in the 4th quarter. Vanguard Group Inc. now owns 1,697,015 shares of the company’s stock worth $70,307,000 after buying an additional 362,060 shares in the last quarter. Woodline Partners LP raised its position in Maze Therapeutics by 10.0% in the 3rd quarter. Woodline Partners LP now owns 1,035,229 shares of the company’s stock worth $26,843,000 after buying an additional 94,529 shares during the last quarter. Finally, Marshall Wace LLP raised its position in Maze Therapeutics by 9.0% in the 4th quarter. Marshall Wace LLP now owns 847,472 shares of the company’s stock worth $35,111,000 after buying an additional 69,771 shares during the last quarter.

Maze Therapeutics Trading Up 2.1%

The company’s 50 day simple moving average is $45.07 and its 200-day simple moving average is $36.16. The firm has a market cap of $2.47 billion, a P/E ratio of -2.45 and a beta of 4.46.

Maze Therapeutics Company Profile

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.